Elsevier Launches QUOSA for iPad Application to Give Mobile Access to Copyright Compliant Literature

AMSTERDAM, March 26, 2014 /PRNewswire/ --

App-based  access  to  cloud-based  library  solution  solves  mobility  challenges  for  Medical  Affairs  teams  and  Medical  Science  Liaisons

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the launch of QUOSA for iPad® supporting professionals in the life sciences, particularly Medical Affairs and Medical Science Liaisons. The iPad app, a further development of the QUOSA literature management tool, enables Medical Affairs teams and Medical Science Liaisons to access pre-approved and copyright compliant literature, which can be read offline, from a central repository. It allows users to find articles from sources such as PubMed and Embase while on the move, resolving issues with appropriate use of content and lack of Internet connectivity during travel, while significantly improving users' productivity and enabling timely meeting preparation.

Without QUOSA, important literature may be stored in shared drives that do not alert users when new, relevant content is available. Consumer data storage and sharing tools are generally not approved for corporate use due to security concerns, while file sizes can quickly make email unwieldy. There is also the threat of large fines if companies do not observe regulatory guidelines, share information that has not been pre-approved, quote literature that recommends off-label use, or fail to report to various regulatory bodies in a timely fashion. Further, Medical Science Liaisons spend a considerable amount of time traveling. QUOSA for iPad ensures professionals can access, annotate and share compliant and approved literature at any time, reducing the need to rely on overflowing inboxes or boot up laptops while traveling or in meetings.

"Content management and workflow productivity is a key strategic area in life sciences that requires support. There have been considerable fines in cases where a pharmaceutical company promotes an off-label drug or uses inaccurate literature when meeting with physicians. As such, robust information management with timely access to copyright compliant and trusted literature is critical," said Meeuwis Van Arkel, Vice President of Product Development. "iPads are becoming far more prevalent in meetings with key opinion leaders. The QUOSA app will enable Medical Science Liaisons to be more self-sufficient by accessing literature on the move, helping them maintain compliance and better prepare for meetings with physicians and healthcare providers."

The QUOSA solution is a centralized repository of scientific literature that enables life sciences institutions to meet regulatory reporting requirements, address medical inquiries and maintain current awareness in relation to topics or authors. It is used by a broad array of groups such as pharmacovigilance and medical affairs personnel in pharma, biotech and medical device companies. Via the iPad application, users will be able to create and manage their own folders of literature.  

QUOSA is part of Elsevier's Life Science Solutions, a portfolio of interoperable, domain-specific, decision support tools which span the discovery and development workflow; including Pathway Studio™, Reaxys ®, Reaxys ® Medicinal Chemistry, ScienceDirect, Scopus, PharmaPendium® and Embase®.

QUOSA for iPad is now available from the Apple® App Store℠ . For further information please visit http://www.elsevier.com/quosa

About  Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions - among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey - and publishes nearly 2,200 journals, including The  Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media  contact
Amy Burnis
Director, Strategic Communications
Elsevier
+1-617-803-8344
a.burnis@elsevier.com